Gwenn Hansen

Gwenn Hansen

Company: Nurix Therapeutics

Job title: Chief Scientific Officer

Seminars:

Roundtable Discussion: Discussing the Utility of Activating or Inactivating Ligases to Strategize a Novel Class of Modulating Drugs 2:30 pm

What is the current progress in identifying inactivating/activating ligases? What are biggest bottlenecks preventing the progression of inactivating/activating ligases? What is the clinical perspective on the development of activating or inactivating ligases?Read more

day: Day Two

Building a DEL-Driven Discovery Pipeline for More Efficient Access to E3 Ligase Binders for Degrader Development 11:00 am

Using a ligand-first approach to speed access to more ligase binders Employing multiple orthoganol methods to survey and confirm novel ligase ligands High-throughput degrader discovery platform enables identification of multiple novel E3 ligase effectorsRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.